Pharmaceutical Co-crystals and Chemistry Characterisation Optimisation of Drug Properties
We are delighted to announce details of our upcoming webinar taking place on Wednesday 27th November at 15:00 GMT
Co-crystallisation is gaining significant interest as an enabling solution for active
pharmaceuticals which have poor or limiting bioavailability, and as a mechanism
for Intellectual Property (IP) protection.
In the 8th webinar in our series, Concept and our partners Malvern Panalytical, bring
together two leading industry experts to present recent developments in the
chemistry, regulation and characterisation of API co-crystals.
Kim James, Lead Chemist at Concept Life Sciences, will discuss co-crystal
fundamental concepts including their design, chemistry, synthesis and scale up.
He will present the advantages conferred to the discovery and development
pathway through co-crystals exhibiting enhanced drug-like properties, together
with the recent evolution in the FDA approach to these forms, and their
viability as development candidates
The presentation from Stjepan Prugovecki (Regional XRD Product Manager EMEA) at
Malvern Panalytical will then cover the relevance of crystal structure in the
characterisation of co-crystals and the methods for determination and
refinement of their crystal structure. It will include discussions on
structural differences and similarities between co-crystals, salts, polymorphs,
hydrates and solvates as well as the role of crystal structure in Intellectual
Property Protection and patents. It will finish with analytical methods for
identification and stability assessment of co-crystals in a bulk pharmaceutical
This webinar will be hosted by Simon Bristow, Chief Technical Officer at Concept
Life Sciences. Simon has over 25 years’ experience in pharmaceutical
development and API process technology research.
The Webinar will be of interest to medicinal chemists, process research
specialists, pre-formulation and materials characterisation scientists and
those involved in pre-clinical drug development.